fusion physical therapy wellness p.c.

1202 lexington avenue ste. 264
new york, new york 10028

NYS Entity Status
ACTIVE

NYS Filing Date
FEBRUARY 14, 2013

NYS DOS ID#
4360296

County
NEW YORK

Jurisdiction
NEW YORK

Registered Agent
NONE

NYS Entity Type
DOMESTIC PROFESSIONAL CORPORATION

Name History
2013 - FUSION PHYSICAL THERAPY WELLNESS P.C.









Buffer



submit to reddit

Telephone
n/a

Fax
n/a

Website
n/a

Email address
n/a

LinkedIn
n/a

Facebook
n/a

Google+
n/a

Twitter
n/a

Pinterest
n/a

Instagram
n/a



  • Around the Web

  • 30 November, 2016 – Episode 595 – This Week in Science Podcast (TWIS)
    By Kirsten Sanford - Thursday Dec 1, 2016

    Weird Quantum Space, Space Eyes, Lucy In The Sky, Not Dead Yet, Old Genes, What The Frack?, Skin You're In, We All Gots Bugs, CRISPR Cures Hemophilia, Boiling Water, Life Choices, And Much More!!!

    Source: This Week in Science
  • Stealthy NY Startup Rocket Pharma Merges With Inotek, Heads to Nasdaq
    By Ben Fidler - Tuesday Sep 12, 2017

    Rocket Pharmaceuticals, a stealthy gene therapy startup in New York City, has made its first splash. Through a merger with struggling Inotek Pharmaceuticals (NASDAQ: ITEK), Rocket, a company developing treatments for a variety of rare blood diseases, has taken itself public. Rocket shareholders are expected to own 81 percent of the combined company, with Inotek […]

    Source: Xconomy New York
  • The Rebuilding Years, Post-Sandy
    By THE NEW YORK TIMES and JONAH MARKOWITZ - Sunday Oct 29, 2017

    Those affected by Hurricane Sandy five years ago shared how the storm changed their lives physically, emotionally and financially, and how things have changed for the better since.

    Source: NYT > Home Page
  • NY insurance company dragged into Wells Fargo scandal
    By Kevin Dugan - Tuesday Aug 1, 2017

    The New York insurance company that wrote policies for 800,000 questionable Wells Fargo auto loans has been dragged into the bank’s latest scandal. National General Insurance was named in a class-action lawsuit filed against the bank — for allegedly unduly profiting from $80 million in collateral protection insurance that the drivers didn’t need — and...

    Source: New York Post: Business
  • FDA Refuses to Review Acorda Parkinson’s Drug, Shares Tumble
    By Ben Fidler - Tuesday Aug 29, 2017

    The heat is on Acorda Therapeutics once again. Months after Acorda lost a key group of patents, the FDA has declined to review, at least for now, an experimental Parkinson’s disease drug that is critical to the company’s future. Acorda (NASDAQ: ACOR) said this morning that the FDA has sent the Ardsley, NY, company a […]

    Source: Xconomy New York